Continuous Renal Replacement Therapy Market to Reach USD 3.66 Billion by 2035, Driven by Rising AKI Cases

The global Continuous Renal Replacement Therapy (CRRT) Market was valued at approximately USD 1.76 billion in 2025 and is projected to reach USD 3.66 billion by 2035, expanding at a CAGR of 8.8% during the forecast period 2026-2035. The market is gaining momentum as the rising incidence of acute kidney injury, chronic kidney disease, sepsis, and multiple organ failure increases demand for continuous renal support in critical care settings. Growing adoption of CRRT in intensive care units, combined with advances in automated treatment systems, filtration technologies, monitoring capabilities, and patient-specific renal support, is further supporting market expansion.

The competitive opportunity is increasingly focused on advanced CRRT systems, treatment automation, precise fluid management, and improved patient monitoring. Growing demand for continuous renal support among critically ill patients is encouraging healthcare providers to adopt technologies that enhance treatment efficiency and enable more personalized therapy. Advances in filtration systems and monitoring technologies are also creating opportunities to improve renal replacement therapy in intensive care environments. The market is therefore shifting toward automated treatment platforms, advanced filtration technologies, real-time monitoring, personalized renal support, and improved critical-care outcomes, supporting sustained growth in the global Continuous Renal Replacement Therapy Market through 2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/continuous-renal-replacement-therapy-market?sai-v

Recent Developments
June 2026: Research in Critical Care highlighted CRRT-miECCO2R, an integrated approach combining continuous renal replacement therapy with extracorporeal CO2 removal. The approach reflects the evolution of CRRT platforms toward broader multiorgan support, combining renal replacement, acid-base management, and extracorporeal CO2 clearance within an integrated treatment strategy.

May 2026: An international ADQI-ELSO consensus addressed the use of CRRT in patients receiving extracorporeal membrane oxygenation (ECMO). The recommendations covered AKI epidemiology, fluid management, indications for CRRT, best practices for combining CRRT with ECMO, biomarkers, extracorporeal blood purification, and drug pharmacokinetics, supporting greater standardization of CRRT use in complex critical-care patients.

April 2026: Research published in Scientific Reports evaluated the use of circuit pressure parameters to predict filter clotting during CRRT. The study found that changes in filter pressure drop and transmembrane pressure were associated with filter coagulation, supporting the development of predictive monitoring approaches that could help clinicians identify circuit clotting earlier and improve treatment continuity.

March 2026: A randomized controlled trial published in Intensive Care Medicine compared integrated and separated CRRT circuits during ECMO support. The study included 80 patients and found no significant difference in median CRRT circuit lifespan between the integration and separation approaches, contributing evidence toward optimizing CRRT delivery for patients requiring simultaneous extracorporeal therapies.

February 2026: Research continued to advance longer-lasting CRRT filter technology. A prospective study of the B. Braun OMNIset Pro filter set evaluated an approved maximum runtime of 96 hours and found sustained clearance of key solutes in circuits that remained patent through the extended period. The development supports efforts to reduce treatment interruptions and improve CRRT circuit efficiency.

Key Players
Baxter International Inc. | Asahi Kasei Corporation | B. Braun Medical Inc. | Medtronic plc | Fresenius Medical Care AG | NxStage Medical, Inc. | Infomed SA | Medica S.p.A. | Medites Pharma spol. s.r.o. | Quanta Dialysis Technologies Inc. | Others

Key Highlights
Baxter International Inc. - Holds a 21.8% share, driven by its strong CRRT product portfolio, established critical-care presence, and broad global healthcare network.

Asahi Kasei Corporation - Holds a 15.6% share, supported by its expertise in blood purification technologies, dialysis systems, and advanced renal care solutions.

B. Braun Medical Inc. - Holds a 13.8% share, strengthened by its comprehensive dialysis portfolio, CRRT solutions, and strong presence across hospitals and critical-care settings.

Medtronic plc - Holds an 10.2% share, supported by its broad medical technology portfolio, global distribution network, and capabilities in renal and critical-care technologies.

Fresenius Medical Care AG - Holds a 9.8% share, driven by its extensive renal-care expertise, dialysis infrastructure, and global presence in kidney disease management.

NxStage Medical, Inc. - Holds a 7.4% share, supported by its focus on innovative dialysis technologies and flexible renal replacement solutions for acute and chronic care settings.

Infomed SA - Holds a 4.6% share, strengthened by its specialized expertise in renal replacement therapies and development of dialysis-related technologies.

Medica S.p.A. - Holds a 3.8% share, supported by its medical technology portfolio and focus on blood purification and extracorporeal treatment solutions.

Medites Pharma spol. s.r.o. - Holds a 2.7% share, driven by its presence in renal-care products and specialized medical solutions.

Quanta Dialysis Technologies Inc. - Holds a 2.3% share, supported by its innovative dialysis technology platform and focus on simplifying renal replacement treatment.

Others - Hold a combined 18.0% share, comprising emerging medical technology companies, specialized renal-care manufacturers, and regional CRRT solution providers.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=continuous-renal-replacement-therapy-market?sai-v

Market Drivers
Rising incidence of acute kidney injury (AKI), chronic kidney disease, sepsis, and multiple organ failure, increasing demand for continuous renal replacement therapy.

Growing adoption of CRRT in critically ill patients who require gradual and continuous fluid and solute removal.

Increasing number of patients admitted to intensive care units with severe renal complications, supporting demand for advanced renal replacement therapies.

Growing preference for CRRT over intermittent dialysis in hemodynamically unstable patients due to its continuous and controlled treatment approach.

Increasing healthcare expenditure and expansion of critical care infrastructure across developed and emerging markets.

Rising adoption of advanced CRRT machines and technologies offering improved treatment monitoring, precision, and clinical workflow.

Increasing awareness among healthcare professionals regarding the role of CRRT in managing critically ill patients with acute renal dysfunction.

Industry Developments
Development of advanced CRRT systems with improved automation, treatment monitoring, safety features, and user-friendly interfaces.

Increasing integration of digital technologies and real-time monitoring capabilities into CRRT systems to improve treatment management.

Strategic collaborations between medical device manufacturers, healthcare providers, and research institutions to advance renal replacement technologies.

Expansion of CRRT product portfolios, including advanced machines, dialysis filters, bloodlines, and specialized consumables.

Growing clinical research evaluating CRRT protocols, treatment strategies, and applications in critically ill patients with complex conditions.

Increasing focus on improving CRRT safety, treatment efficiency, fluid management, and patient outcomes in intensive care settings.

Regional Insights
North America - 41% share: "Driven by advanced critical care infrastructure, high adoption of renal replacement technologies, increasing incidence of acute kidney injury, and strong healthcare expenditure."

Europe - 30% share: "Supported by established intensive care networks, advanced dialysis infrastructure, increasing adoption of CRRT, and growing focus on critical care management."

Asia Pacific - 23% share: "Fueled by the rising burden of kidney diseases, expanding intensive care infrastructure, increasing healthcare expenditure, and growing adoption of advanced renal replacement technologies."

Latin America - 4% share: "Supported by improving critical care infrastructure, increasing awareness of CRRT, and expanding access to advanced renal replacement therapies."

Middle East & Africa - 2% share: "Driven by improving hospital infrastructure, increasing availability of intensive care services, rising kidney disease burden, and growing adoption of advanced CRRT systems."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/continuous-renal-replacement-therapy-market?sai-v

Key Segments
➥ By Product Type

Dialysate and Replacement Fluids: Represents a significant segment, driven by their essential role in maintaining fluid balance, removing metabolic waste, and supporting continuous renal replacement therapy in critically ill patients.

Disposables: Represents a dominant segment, supported by the recurring need for sterile, single-use components during CRRT procedures and the increasing number of treatments performed in intensive care settings.

Bloodline Sets: Represents a significant segment, fueled by their essential function in maintaining safe extracorporeal blood circulation and the continued demand for replacement sets during CRRT procedures.

Hemo-filters: Represents a major segment, driven by their critical role in removing excess fluid, electrolytes, and metabolic waste from the blood during continuous renal replacement therapy.

Other Disposables: Represents a growing segment, supported by continued demand for specialized single-use components required for efficient and safe CRRT procedures.

Systems: Represents a significant segment, driven by increasing adoption of advanced CRRT machines, technological improvements in treatment monitoring, and the growing need for precise fluid and therapy management.

➥ By Application Type

Slow Continuous Ultra Filtration: Represents a significant segment, supported by its use for controlled fluid removal in critically ill patients, particularly those requiring gradual management of fluid overload.

Continuous Veno Venous Hemo-Filtration: Represents a dominant segment, driven by its widespread use for continuous removal of solutes and fluid in patients with acute kidney injury and critical illness.

Continuous Veno Venous Hemo-Dialysis: Represents a significant segment, fueled by the ability to provide continuous clearance of metabolic waste and electrolytes while supporting fluid management in intensive care settings.

Continuous Veno Venous Hemo-Diafiltration: Represents a growing segment, supported by its combined convective and diffusive clearance capabilities and increasing adoption for comprehensive blood purification in critically ill patients.

➥ By Therapy Type

Renal: Represents the dominant segment, driven by the increasing use of CRRT for acute kidney injury, severe renal dysfunction, and fluid and electrolyte management in critically ill patients.

Non-Renal: Represents a growing segment, supported by the use of blood purification approaches for selected non-renal critical care applications and broader clinical interest in extracorporeal therapies.

Combination of Both: Represents an expanding segment, fueled by the increasing integration of renal and non-renal therapeutic approaches in complex critical care cases requiring comprehensive extracorporeal support.

➥ By End-User

Hospitals: Represents the dominant segment, driven by the high prevalence of critically ill patients requiring CRRT, increasing incidence of acute kidney injury, and availability of intensive care infrastructure and specialized clinical teams.

Ambulatory Surgery Clinics: Represents a growing segment, supported by the expansion of specialized renal care services and increasing availability of advanced extracorporeal treatment infrastructure in outpatient healthcare settings.

Others: Represents an emerging segment, supported by the adoption of CRRT-related technologies across specialized healthcare facilities and other clinical settings requiring continuous renal support.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.